Description

Insulet Corporation’s Hidden Omnipod Story Behind 59% International Revenue Growth!

Insulet Corporation reported a strong start to 2026, with total revenues of $762 million in the first quarter, reflecting a 34% year-over-year increase on a reported basis and 30% on a constant currency basis. Omnipod revenue grew 33% constant currency, driven by increased adoption of the Omnipod 5 insulin management system across both U.S. and international markets. The company’s global customer base expanded nearly 25% year-over-year, supported largely by conversions from multiple daily injections (MDI) to automated insulin delivery (AID). U.S. revenue grew 28%, exceeding guidance, although new customer starts declined sequentially due to seasonal headwinds attributed to deductible resets affecting co-pays and coinsurance. International revenue grew 59% reported (45% constant currency), with strong growth in established European markets and expansion into new markets such as Canada and the upcoming planned launch in Spain. Gross margins reached 69.